PT - JOURNAL ARTICLE AU - Spranger, Leonard AU - Bredow, Josephine AU - Zeitz, Ulrike AU - Grittner, Ulrike AU - Boschmann, Michael AU - Dickmann, Sophia AU - Stobäus, Nicole AU - Jumpertz-von Schwartzenberg, Reiner AU - Spranger, Joachim AU - Mai, Knut TI - Thrifty energy phenotype predicts weight regain - results of a randomized controlled trial AID - 10.1101/2021.03.25.21254300 DP - 2021 Jan 01 TA - medRxiv PG - 2021.03.25.21254300 4099 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254300.short 4100 - http://medrxiv.org/content/early/2021/03/26/2021.03.25.21254300.full AB - Background & Aims Weight loss is associated with an improvement of insulin sensitivity. Both, a negative energy balance and changes of body composition are integrative components of weight loss interventions. However, the individual impact of these two components on insulin sensitivity and energy metabolism is unclear.Methods We performed a randomized controlled trial including 80 overweight or obese post-menopausal women. Participants randomly assigned to the intervention group underwent an 800 kcal/d liquid diet for 2 months followed by four weeks in which the formula diet was substituted by a calorie reduced healthy diet to facilitate further weight loss. This weight loss phase was followed by a 4-week weight maintenance phase, where weight stability was achieved by individualized daily caloric intake without negative energy balance. Volunteers of the control group were instructed to keep their weight stable during the entire period of 4 months. Metabolic phenotyping was performed in both groups at baseline (M0), after weight loss (M3) and after the maintenance period (M4). Additional phenotyping was performed during follow-up at 12 (M12) and 24 months (M24). Primary outcomes were changes of lean body mass (LBM) and changes of insulin sensitivity (ISIClamp) between baseline and M3 and M4. Estimates of energy metabolism were secondary endpoints.Results No significant changes of body weight or LBM were found in the control group between any time points. A significant reduction of body weight, fat mass (FM) and LBM was found in the intervention group between M0 and M3, while no further change was seen between M3 and M4. Only subjects of the intervention group were characterized by an improvement of the second primary outcome ISIClamp at M3, which was preserved until M4. Notably, a lower resting energy expenditure per LBM (REELBM) at M3 as well as the individual difference of REELBM between M3 and M4 significantly predicted a stronger regain of fat mass during follow-up.Conclusions In summary, our data demonstrate that modulation of LBM and insulin sensitivity during weight loss is predominantly driven by changes in body weight and body composition, rather than an individual effect of negative energy balance. However, the variance in energy expenditure during negative and steady energy balance indicates a thrifty phenotype, which is highly susceptible to future regain of fat mass.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01105143Funding StatementThis research was supported by the Deutsche Forschungsgemeinschaft (DFG KFO 192), the German Diabetes Society (DDG) and the German Ministry for Education and Research (BMBF) by support of the German Centre for Cardiovascular Research (DZHK; BER5.1) and the German Center for Diabetes Research (DZD).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocols were approved by the Institutional Review Board of the Charite Medical School (EA1/140/12) and all subjects gave written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.